Abacavir lamivudine zidovudine indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Abacavir lamivudine zidovudine}} {{CMG}}; {{AE}} {{SS}} ==Indications And Usage== TRIZIVIR is indicated in combination with other antiretrovirals or alone for the...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
*TRIZIVIR is one of multiple products containing [[abacavir]]. Before starting TRIZIVIR, review medical history for prior exposure to any [[abacavir]]-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to [[abacavir]] [see Warnings and Precautions (5.1), Adverse Reactions (6)]. | *TRIZIVIR is one of multiple products containing [[abacavir]]. Before starting TRIZIVIR, review medical history for prior exposure to any [[abacavir]]-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to [[abacavir]] [see Warnings and Precautions (5.1), Adverse Reactions (6)]. | ||
*TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3 components.*Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRIZIVIR (ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b32f5a4-d0f7-486b-b699-8dc9202b6869#nlm34089-3 | publisher = | date = | accessdate = 9 January 2014 }}</ref> | *TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: [[abacavir]], [[lamivudine]], and [[zidovudine]] and is intended only for patients whose regimen would otherwise include these 3 components.<BR> | ||
*Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRIZIVIR (ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b32f5a4-d0f7-486b-b699-8dc9202b6869#nlm34089-3 | publisher = | date = | accessdate = 9 January 2014 }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 16:43, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications And Usage
TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection.
Additional important information on the use of TRIZIVIR for treatment of HIV-1 infection:
- TRIZIVIR is one of multiple products containing abacavir. Before starting TRIZIVIR, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1), Adverse Reactions (6)].
- TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3 components.
- Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)].[1]
References
- ↑ "TRIZIVIR (ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY]". Retrieved 9 January 2014.
Adapted from the FDA Package Insert.